(S)-Lansoprazole

Product Name(S)-Lansoprazole
CAS138530-95-7
MFC16H14F3N3O2S
MW369.36
EINECS
MOL File138530-95-7.mol

Chemical Properties

Melting point	60-65°C
Boiling point	555.8±60.0 °C(Predicted)
Density	1.50±0.1 g/cm3(Predicted)
storage temp.	Sealed in dry,Store in freezer, under -20°C
solubility	Chloroform (Slightly), Methanol (Slightly)
form	Solid
pka	9.56±0.10(Predicted)
color	Beige to Light Brown

Usage And Synthesis

Description

(S)-Lansoprazole is a proton pump inhibitor that irreversibly inhibits H⁺/K⁺-stimulated ATPase pumps in parietal cells (IC₅₀ = 5.2 μM), inhibiting gastric acid secretion and increasing intragastric pH. It also inhibits acid formation in isolated canine parietal cells (IC₅₀ = 82 μM). (S)-Lansoprazole is an enantiomerically pure form of lansoprazole . Both (S)- and (R)-lansoprazole are pharmacologically active with similar potencies.

Chemical Properties

Light Brown Solid

Uses

The S-enantiomer of Lansoprazole; a gastric proton pump inhibitor. An antiulcerative.

in vivo

Lansoprazole (20-40 mg/kg) treatment significantly attenuated STZ and HFD -induced memory deficits, biochemical and histopathological alterations^[3].
Lansoprazole (20 mg/kg and 40 mg/kg, p.o.) significantly reduces the STZ and HFD- induced increase in AChE activity^[3].
Lansoprazole (20 mg/kg and 40 mg/kg, p.o.) significantly reduces the STZ and HFD- induced rise in brain MPO level^[3].
Further HFD mice treated with lansoprazole (20 mg/kg and 40 mg/kg, p.o.) shows a marked decrease in the body weight in comparison to the control animals^[3].

References

[1] SCHUBERT M L. Pharmacotherapy for acid/peptic disorders.[J]. Yale Journal of Biology and Medicine, 1996, 69 2: 197-201.